• Definium Therapeutics is trading 19.35% up in pre-market at $46.41 following the announcement of positive topline results from its Phase 3 Panorama study of DT120 ODT in generalized anxiety disorder.
  • The company announced the study met its primary and all key secondary efficacy endpoints, demonstrating a statistically significant reduction in Hamilton Anxiety Rating Scale (HAM-A) score.
  • Definium Therapeutics is hosting a webcast today, September 14, 2026, at 8:00 a.m. EDT to discuss these results.